Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.42 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2996984 | 1.00 | SMYD3 (0.42) | SMYD3PLATGAATSHRHPGD | |
| SCHEMBL3658061 | 1.00 | SMYD3 (0.42) | SMYD3PLATGAATSHRHPGD | |
| SCHEMBL2996988 | 1.00 | SMYD3 (0.42) | SMYD3PLATGAATSHRHPGD | |
| SCHEMBL14359459 | 0.92 | SLC6A1 (0.49) | SMYD3PLATGAATSHRHPGD | |
| SCHEMBL8449068 | 0.90 | GAA (0.47) | PLATGAATSHRHPGDMAPT | |
| SCHEMBL23128400 | 0.81 | CNR2 (0.37) | TSHRMAPTPARP1SLC6A1SMN1; SMN2 | |
| SCHEMBL8216961 | 0.81 | DPP4 (0.37) | PLATGAAHPGDDPP4FAP | |
| SCHEMBL22893351 | 0.80 | MAPT (0.59) | GAATSHRHPGDMAPTSMN1; SMN2 | |
| SCHEMBL15730093 | 0.78 | GAA (0.64) | GAATSHRHPGDMAPTSMN1; SMN2 | |
| SCHEMBL6185245 | 0.78 | GAA (0.64) | GAATSHRHPGDMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205558-B1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF AS HISTAMINE H3 RECEPTOR MODULATORS | SANOFI SA (FR) | 2012-07-25 | — | — | EP | disclosed |
| US-8227504-B2 | Substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof | SANOFI (FR) | 2012-07-24 | — | — | US | disclosed |
| US-8227504-B2 | Substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof | SANOFI (FR) | 2012-07-24 | — | — | US | disclosed |
| US-8227504-B2 | Substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof | SANOFI (FR) | 2012-07-24 | — | — | US | disclosed |
| US-20100173898-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
| US-20100173898-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
| US-20100173898-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
| WO-2009052063-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF AS HISTAMINE H3 RECEPTOR MODULATORS | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173898-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF | HRH3, HRH4, CNR1 | SMYD3 997/4885PLAT 4083/4885GAA 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.